Your browser doesn't support javascript.
loading
Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder
Psychiatry Investigation ; : 102-105, 2008.
Artículo en Inglés | WPRIM | ID: wpr-33386
ABSTRACT

OBJECTIVE:

We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.

METHODS:

A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).

RESULTS:

There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.

CONCLUSION:

Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Farmacogenética / Trastorno Bipolar / Ácido Valproico / Antimaníacos Límite: Humanos Idioma: Inglés Revista: Psychiatry Investigation Año: 2008 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Farmacogenética / Trastorno Bipolar / Ácido Valproico / Antimaníacos Límite: Humanos Idioma: Inglés Revista: Psychiatry Investigation Año: 2008 Tipo del documento: Artículo